Bhavini Mishra, Sanket Koul

Stories by Bhavini Mishra, Sanket Koul

Weight Loss Drugs Sales Surge!

Weight Loss Drugs Sales Surge!

Rediff.com   8 hours ago

'The innovators have been able to more or less stay where they are, in terms of revenue even as the generics are seeing exponential growth due to their affordability.'

Affordable housing may lose more ground as costs rise

Affordable housing may lose more ground as costs rise

Rediff.com   5 May 2026

The ongoing West Asia conflict is expected to severely impact the supply of affordable housing in India, as rising input costs further erode already thin developer margins. Fluctuations in crude oil and gas prices, coupled with higher freight costs, are driving up prices of essential construction materials like cement and steel, making new projects increasingly unviable for developers.

SC refuses to interfere in NCLAT order restoring Byju's committee of creditors

SC refuses to interfere in NCLAT order restoring Byju's committee of creditors

Rediff.com   5 May 2026

The Supreme Court has dismissed an appeal by Byju Raveendran, upholding the NCLAT's decision to reinstate the original Committee of Creditors (CoC) in Think & Learn Private Ltd's insolvency proceedings, which includes Glass Trust Company LLC as a major lender.

Chinese API price surge tests India's pharma buffers amid West Asia crisis

Chinese API price surge tests India's pharma buffers amid West Asia crisis

Rediff.com   2 May 2026

India's pharmaceutical industry is experiencing increased bulk drug prices, particularly for APIs from China, following the escalation of the West Asia crisis in March. While current inventories provide a temporary buffer, concerns are mounting over the availability of key solvents and feedstocks, potentially leading to manufacturing disruptions and shortages in specific drug categories.

Canada first G7 nation to okay Dr Reddy's generic version of semaglutide

Canada first G7 nation to okay Dr Reddy's generic version of semaglutide

Rediff.com   30 Apr 2026

Dr Reddy's Laboratories has received approval from Health Canada to sell a generic version of the diabetes drug semaglutide, making it the first company to get market authorisation for a generic semaglutide injection in Canada and the first in a G7 country.

Pressure builds on developers to hike prices as costs rise

Pressure builds on developers to hike prices as costs rise

Rediff.com   13 Apr 2026

Indian realty developers are contemplating price increases for ongoing and upcoming projects to offset margin pressures caused by rising input costs and supply chain disruptions, exacerbated by the West Asia conflict. Input and labour costs have surged by 5-12%, directly impacting developer margins, especially for under-construction projects.

Supreme Court: No personal hearing needed before banks tag loan accounts as fraud

Supreme Court: No personal hearing needed before banks tag loan accounts as fraud

Rediff.com   8 Apr 2026

The Supreme Court has ruled that borrowers are not entitled to a personal hearing before banks classify their loan accounts as "fraud" under RBI directions, clarifying that a written response to a show-cause notice and access to the forensic audit report (with redactions) are sufficient for natural justice.

Indian HNIs maintain grip on Dubai luxury real estate despite West Asia tensions

Indian HNIs maintain grip on Dubai luxury real estate despite West Asia tensions

Rediff.com   6 Apr 2026

Ongoing geopolitical tensions in West Asia have slowed deal momentum in Dubai's luxury residential market, but Indian high-net-worth individuals (HNIs) are not exiting their marquee assets, with any 'discounted' resale deals attributed to investor liquidity stress rather than geopolitical flight.

Noida International Airport: Property Prices Soar Along Yamuna Expressway

Noida International Airport: Property Prices Soar Along Yamuna Expressway

Rediff.com   30 Mar 2026

The inauguration of Noida International Airport (NIA) is set to significantly increase property values in micro-markets along the Yamuna Expressway, with projections indicating a 28 per cent rise for plots and 22 per cent for apartments over the next two years, according to Colliers.

Women Lawyers Face Steep Career Barriers

Women Lawyers Face Steep Career Barriers

Rediff.com   26 Mar 2026

Nearly two-thirds (63.7 per cent) said they had, at some stage, found the profession discouraging.

Centre Cracks Down on GLP-1 Drug Misuse

Centre Cracks Down on GLP-1 Drug Misuse

Rediff.com   25 Mar 2026

Inspections conducted across 49 entities including pharmacies, wholesalers, and clinics to detect violations and misleading marketing practices.

Semaglutide Ruling Sparks Generic Pharma Boom

Semaglutide Ruling Sparks Generic Pharma Boom

Rediff.com   24 Mar 2026

At the heart of this debate is Section 3(d) of the Patents Act, a safeguard designed to prevent drugmakers from extending monopoly protection through trivial modifications to existing medicines.

Anil Ambani seeks debt treatment like Sterling's Sandesaras'

Anil Ambani seeks debt treatment like Sterling's Sandesaras'

Rediff.com   24 Mar 2026

Industrialist Anil Ambani has approached the Supreme Court seeking a court-facilitated debt resolution similar to the one provided to Sterling group's Nitin and Chetan Sandesara, and five other members of their families.

Reality check gets India on investors' realty list

Reality check gets India on investors' realty list

Rediff.com   23 Mar 2026

Escalating geopolitical tensions in West Asia are prompting investors with exposure to Dubai's real estate market to reassess their portfolios. And, in this rejig, India is emerging as a stable destination for capital investment and long-term growth.

SC wants Centre to bring law on paternity leave

SC wants Centre to bring law on paternity leave

Rediff.com   18 Mar 2026

The Supreme Court on Tuesday called on the Union government to enact a legal framework recognising paternity leave as a component of social security, stressing that caregiving responsibilities must be shared between both parents.

Weight Loss Drugs Set to Flood India

Weight Loss Drugs Set to Flood India

Rediff.com   16 Mar 2026

While the introduction of branded generics is likely to accelerate volumes for GLP-1 agonists, value growth may moderate because of price erosion.

US Business Schools Eye India Partnerships

US Business Schools Eye India Partnerships

Rediff.com   12 Mar 2026

The outreach comes amid a drop in Indian student enrolments in management programmes at American universities last year, following changes to US student visa policies.

Obesity Drug Can't Be Advertised Anymore

Obesity Drug Can't Be Advertised Anymore

Rediff.com   12 Mar 2026

'Any promotional activity carried out under the pretext of disease awareness, influencer engagement, corporate campaigns, or similar activities that create brand recall/product visibility of the prescription shall also be treated as violations.'

India Targets 200,000 Foreign Students by 2030

India Targets 200,000 Foreign Students by 2030

Rediff.com   11 Mar 2026

The government has intensified its Study in India programme and is working closely with universities and states to achieve this goal.

Abbott Bets On Semaglutide Boom

Abbott Bets On Semaglutide Boom

Rediff.com   28 Feb 2026

Abbott will exclusively distribute and market Extensior in the country, becoming the second company to secure sole distribution rights for Novo's semaglutide portfolio in India, after Emcure Pharma.